Summary & Overview
HCPCS J7170: Injection of Emicizumab-kxwh, 0.5 mg
HCPCS Level II code J7170 designates a 0.5 mg injection of emicizumab-kxwh, an injectable biologic used to prevent bleeding in people with hemophilia A. Nationally, accurate coding for emicizumab is important for clinical documentation, payer claims processing, and tracking utilization of high-cost specialty therapies. This code matters due to the drug’s role in chronic management and the budgetary impact of biologic hemophilia therapies.
Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of reimbursement benchmarks and coverage considerations across major national payers, common billing practices for unit-based biologic injection codes, and clinical context on the service type and typical administration sites. The summary covers how J7170 is used on service lines to represent 0.5 mg units of emicizumab-kxwh and what that implies for dosing calculations and claim line construction.
The publication provides practical reference material: national benchmarking data where available, policy updates relevant to specialty injectable biologics, and concise clinical context to support accurate use of HCPCS Level II code J7170 in claims and reporting. Data not available in the input are noted where applicable.
Billing Code Overview
HCPCS Level II code J7170 represents an injection of emicizumab-kxwh, 0.5 mg. This code denotes administration of a specified unit dose of emicizumab-kxwh, a bispecific monoclonal antibody used in the management of hemophilia A.
Service type: Injection (parenteral therapeutic administration)
Typical site of service: Outpatient clinic, physician office, infusion center, or other ambulatory care settings where injectable biologic therapies are administered
Data not available in the input on associated taxonomies, ICD-10 diagnoses, related codes, or specific service line.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adolescent or adult with congenital hemophilia A with factor VIII inhibitors or a patient with acquired hemophilia A requiring prophylaxis or treatment to reduce bleeding risk. The medication J7170 (injection, emicizumab-kxwh, 0.5 mg) is administered subcutaneously as a monoclonal bispecific antibody that substitutes for activated factor VIII activity. Clinical workflow: the patient presents to an infusion clinic, hematology clinic, or specialty pharmacy-coordinated clinic for dosing. The clinician documents diagnosis, weight-based dosing schedule, and prior factor/inhibitor history; pharmacy prepares unit-based vials or syringes; nursing verifies identity and performs subcutaneous injection, observes the patient for infusion reaction or local site reaction for a monitored period (typically 30–60 minutes on initiation), and documents lot number, NDC, and amount administered in milligrams and corresponding units of J7170. Follow-up visits occur per hematology protocol for efficacy and safety monitoring; treatment may continue in outpatient infusion centers, physician offices, or home administration by trained caregivers or home health nurses.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug amount discarded/not administered | When a portion of a single-use vial/syringe of is discarded and documentation supports wastage |